Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (Bat)
Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) is an FDA-licensed reference biologic from Emergent BioSolutions Canada Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2013
Reference approved
Reference product
Bat Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)
Emergent BioSolutions Canada Inc.
- Approved
- Mar 22, 2013
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine), in chronological order.
Reference approval
Approval date of the reference Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) product.
13 yr 5 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
6 yr 3 mo ago
Frequently asked questions
Are there biosimilars approved for Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (Bat)?
No 351(k) biosimilars or interchangeable biosimilars referencing Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.